ReviewJournal of cancer research and clinical oncology2026
The pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiers.
Review in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated macrophages (TAMs) are among the most abundant cells in the tumor microenvironment (TME), with M1 and M2 polarization exhibiting anti-tumorigenic and tumorigenic functions, respectively. Originating from both embryonic precursors and circulating monocytes derived from hematopoietic stem cells, TAMs acquire distinct transcriptional, metabolic, and functional identities shaped by the TME. The interactions in the TME among various cells, including cancerous and non-cancerous cells, can determine the polarization and function of TAMs within the tumor. More recently, TAMs have garnered significant interest as a promising therapeutic target in oncology. The TAMs have been shown to enhance proliferation, metastasis, and angiogenesis in human cancers. Notably, cytokines and chemokines, among others, can regulate the infiltration of TAMs in TME. Given the crucial role of macrophages in regulating inflammation and immune responses, targeting these cells has become a significant focus in cancer immunotherapy. Currently, macrophages have been targeted through three strategies, including suppressing macrophage/monocyte recruitment, depletion of TAMs, and re-education of TAMs. Each of these approaches is being investigated in preclinical models and clinical trials, either as monotherapy or in combination with immune checkpoint inhibitors. TAMs can also be engineered to act as drug delivery tools, carrying nanoparticles directly into tumors. In the clinic, some types of TAMs, marked by proteins like CD163 and CD204, can help predict patient outcomes in several cancers. This review investigates the origins of TAMs and the mechanisms underlying their polarization and metabolism. Furthermore, we study macrophage-driven tumor progression and devising effective targeting strategies, as well as challenges that remain and where the field may go next in macrophage-based cancer treatment. Going forward, combining single-cell profiling with multi-target therapies may offer the best path toward more effective, TAM-based cancer treatments.
Indexed as
Identifiers
42911425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.